# A Double Blind Placebo Controlled Study to Assess the Efficacy on Joint Damage in RA Patients

> **NCT00319917** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 123 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** tacrolimus
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00319917
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2014-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00319917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00319917, "A Double Blind Placebo Controlled Study to Assess the Efficacy on Joint Damage in RA Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00319917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*